In October, Sutter reached a preliminary agreement in an antitrust case brought by employers and later joined by California Attorney General Xavier Becerra. If approved, the settlement will resolve allegations that Sutter Health violated California’s antitrust laws by using its market power to overcharge patients and employer-funded health plans. The class members alleged Sutter Health’s inflated prices led to $756 million in overcharges, according to Bloomberg Law.
“While Sutter Health maintains its contracting practices were, and remain, in compliance with industry standards, it also believes the settlement avoids a protracted trial and years of appeals, which would not be in the best interest of its patients,” states a notice to bondholders filed by Sutter Nov. 25.
In the notice, Sutter said it is bound by court-ordered confidentiality requirements regarding the tentative agreement.
“Due to these confidentiality requirements, Sutter Health will delay posting of its third quarter financial statements and certain updated disclosure information until the court permits the sharing of the terms of the settlement,” the notice states.
A hearing on a motion for preliminary approval of the settlement is scheduled for Feb. 25, 2020, and a hearing on a motion for final approval is expected to occur in summer 2020.
More articles on healthcare finance:
Arizona hospital closes: 4 things to know
Ascension’s revenue climbs to $6.5B in Q1 of fiscal 2020
CommonSpirit’s operating loss quadruples as it awaits California provider fee income
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
